Any current/future new fundraising through debt or equity?

LASA Supergenerics is not raising new debt; all recent capex has been funded through internal accruals (debt-free capex). The company is focusing on generating cash surplus on the balance sheet, aiming for around Rs. 200-300 Crores cash surplus. There is no mention of any immediate equity fundraising; the company prefers organic growth through project execution rather than acquiring new companies. Post-merger with Harishree, paid-up capital will increase from Rs. 40 Crores to Rs. 50 Crores, but this is related to the merger process and not fresh equity raising. Management emphasized a strategy

Any current/future capex/capital investment/strategic investment?

LASA is undertaking capex primarily through internal accruals, maintaining a debt-free status for expansions. Capex includes adding new reactors (17-18 procured recently) for new blockbuster products with large market potential (~Rs. 2000 Crores product). Expansion involves new unit (Unit II) and debottlenecking existing units; full plant capacity expected to be reached in about one year. Backward integration efforts ongoing, especially in Albendazole production to improve cost control and competitiveness. Brownfield expansions planned using available land bank (50 acres, with only 5 acres cur

Future growth expectations in sales/revenue/volumes?

The company expects a sustainable year-on-year growth of around 20% in sales/revenue. There is a plan to launch two blockbuster products with strong and consistent market demand, each with a large market size (one around Rs. 2000 Crores). Export contribution has increased significantly to 40%, boosting revenue growth from new geographies like Russia and the Middle East. Expansion through new units and debottlenecking existing plants will support volume growth. The company emphasizes focusing on core products with low risk profiles rather than diversifying excessively. Growth is targeted throug

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects a sustainable year-on-year growth of around 20% in revenues and PAT. Quarter-on-quarter growth is seasonal and impacted by regulatory issues, so annual evaluation based on PAT is recommended. EBITDA margins are expected to fluctuate between 20% and 25%, with current margins around 22-23%, considered sustainable barring unforeseen events. The company is launching two blockbuster products with a single-product market size around Rs. 2000 Crores, expected to drive growth over the next 2-3 years. Exports have increased to 40% of revenue, contributing significantly to ma

Lasa Supergenerics LtdQ1 FY22Pharmaceuticals & Biotechnology

Lasa Supergenerics Ltd Q1 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹4.67Market Cap: ₹23 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

The company expects a sustainable year-on-year growth of around 20% in sales/revenue.
There is a plan to launch two blockbuster products with strong and consistent market demand, each with a large market size (one around Rs. 2000 Crores).
Export contribution has increased significantly to 40%, boosting revenue growth from new geographies like Russia and the Middle East.
Expansion through new units and debottlenecking existing plants will support volume growth.
The company emphasizes focusing on core products with low risk profiles rather than diversifying excessively.
Growth is targeted through backward integration to improve cost efficiency, particularly in Albendazole.
Despite seasonal factors and regulatory challenges, long-term annual growth guidance remains robust around 20%.
Improved demand trends post-pandemic and focus on cash flow enhancement provide a positive outlook for breaking past records in upcoming years.

Margin guidance

Category 3

The company expects a sustainable year-on-year growth of around 20% in revenues and PAT.
Quarter-on-quarter growth is seasonal and impacted by regulatory issues, so annual evaluation based on PAT is recommended.
EBITDA margins are expected to fluctuate between 20% and 25%, with current margins around 22-23%, considered sustainable barring unforeseen events.
The company is launching two blockbuster products with a single-product market size around Rs. 2000 Crores, expected to drive growth over the next 2-3 years.
Exports have increased to 40% of revenue, contributing significantly to margin expansion and top-line growth.
Operating cash flows are strong, with zero finance cost and improved return on capital focus, enabling capex through internal accruals without debt.
Overall, the outlook suggests consistent topline growth with improved profitability and EPS growth driven by product launches and operational efficiencies.

See what Lasa Supergenerics Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

LASA Supergenerics is not raising new debt; all recent capex has been funded through internal accruals (debt-free capex).
The company is focusing on generating cash surplus on the balance sheet, aiming for around Rs. 200-300 Crores cash surplus.
There is no mention of any immediate equity fundraising; the company prefers organic growth through project execution rather than acquiring new companies.
Post-merger with Harishree, paid-up capital will increase from Rs. 40 Crores to Rs. 50 Crores, but this is related to the merger process and not fresh equity raising.
Management emphasized a strategy to improve cash flow and maintain a debt-free balance sheet rather than raising new capital through debt or equity in the near term.

Order book

The transcript does not provide explicit details about the current or expected order book or pending orders for LASA Supergenerics Limited. However, relevant insights include: - The company experienced a decline in topline during Q4 FY2021 due to fewer government tenders as focus shifted to vaccine procurement during the COVID-19 pandemic. - Recent trends indicate an improvement in demand and growth is expected to cross previous records in the current financial year. - The export business has seen a phenomenal jump, growing from 17% to 40% of revenues due to new geographic registrations (e.g., Russia). - The company anticipates a sustainable year-on-year growth of around 20%. - New blockbuster products with large market potential are expected to contribute to growth in the coming 2-3 years. No specific order book or pending order figures are disclosed in this call.

See what Lasa Supergenerics Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

LASA is undertaking capex primarily through internal accruals, maintaining a debt-free status for expansions.
Capex includes adding new reactors (17-18 procured recently) for new blockbuster products with large market potential (~Rs. 2000 Crores product).
Expansion involves new unit (Unit II) and debottlenecking existing units; full plant capacity expected to be reached in about one year.
Backward integration efforts ongoing, especially in Albendazole production to improve cost control and competitiveness.
Brownfield expansions planned using available land bank (50 acres, with only 5 acres currently used) and environment clearances.
Focus is on project execution rather than acquiring new companies, aiming high ROI (~10x capex).
Upcoming press releases will detail new product launches and capex specifics.
Strategic aim to bring 200-300 Crores cash surplus on balance sheet through organic growth and expansion.

Track Lasa Supergenerics Ltd — get its next earnings analysis in your feed

How does Lasa Supergenerics Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisLasa Supergenerics Ltd

Rev 2Mar 3

See where Lasa Supergenerics Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Lasa Supergenerics Ltd rank in Pharmaceuticals & Biotechnology?

Compare Lasa Supergenerics Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY22) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Lasa Supergenerics Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Accretion Pharmaceuticals Ltd (Q2 FY27)
25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →